Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting

This publication has 13 references indexed in Scilit:

• Antiemetic action of 5-HT3 receptor antagonists: review of preclinical and clinical results with ICS 205–930
  Cancer Treatment Reviews, 1990
• Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
  New England Journal of Medicine, 1990
• The Natural Course of Emesis After Carboplatin Treatment
  Acta Oncologica, 1990
• The effect of three dose levels of ICS 205–930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomiting
  European Journal of Cancer and Clinical Oncology, 1989
• Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial
  Cancer, 1987
• FIRST RESULTS WITH ICS 205-930 (5-HT3 RECEPTOR ANTAGONIST) IN PREVENTION OF CHEMOTHERAPY-INDUCED EMESIS
  The Lancet, 1987
• Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients
  Cancer, 1985
• Nausea and Vomiting as Major Complications of Cancer Chemotherapy
  Drugs, 1983
• Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
  Cancer Chemotherapy and Pharmacology, 1982
• Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting
  New England Journal of Medicine, 1981